Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 37, 2016, Pages 59402-59416

  Wang, Guojing ^a,c   Jia, Tingting ^d   Xu, Xixia ^b   Chang, Le ^a,c   Zhang, Rui ^a   Fu, Yu ^a,c   Li, Yulong ^a,c   Yang, Xin ^a,c   Zhang, Kuo ^a   Lin, Guigao ^a   Han, Yanxi ^a   Li, Jinming ^a,c  

^a BEIJING HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

MiR 122; MS2 VLP; Phage surface display; TAT peptide

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 122; TRANSACTIVATOR PROTEIN; CELL PENETRATING PEPTIDE; MIRN122 MICRORNA, HUMAN; PEPTIDE FRAGMENT; TAT PEPTIDE (47-57), HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; ENTEROBACTERIA PHAGE MS2; FEMALE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OSTEOPOROSIS; PATHOGENESIS; PHAGE DISPLAY; PROTEIN EXPRESSION; RNA INTERFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS LIKE AGENT; WESTERN BLOTTING; ANIMAL; CELL GROWTH; CELL MEMBRANE; DRUG DELIVERY SYSTEM; GENETICS; HEP-G2 CELL LINE; LEVIVIRUS; LIVER TUMOR; METABOLISM; PHYSIOLOGY; VIRION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL MEMBRANE; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HEP G2 CELLS; HUMANS; LEVIVIRUS; LIVER NEOPLASMS; MICE; MICRORNAS; PEPTIDE FRAGMENTS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRION;

EID: 84991328244     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10681     Document Type: Article

References (50)

1. Forner A, Llovet JM and Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2012; 379:1245-1255
2. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016; 66:7-30
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J. Cancer statistics in China, 2015. CA: a cancer journal for clinicians. 2016; 66:115-132
4. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C and Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008; 47:82-89
5. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z and Zhou J. Tumor-Associated Neutrophils Recruit Macrophages and T-regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Gastroenterology. 2016
6. Qin LX and Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. Journal of cancer research and clinical oncology. 2004; 130:497-513
7. Borel F, Konstantinova P and Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. Journal of hepatology. 2012; 56:1371-1383
8. Yang N, Ekanem NR, Sakyi CA and Ray SD. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Advanced drug delivery reviews. 2015; 81:62-74
9. Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer discovery. 2016; 6:235-246
10. Ling H, Fabbri M and Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews Drug discovery. 2013; 12:847-865
11. Bouchie A. First microRNA mimic enters clinic. Nature biotechnology. 2013; 31:577
12. Li XJ, Ren ZJ and Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. Cell death & disease. 2014; 5:e1327
13. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L and Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer research. 2007; 67:6092-6099
14. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P and Ghoshal K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. The Journal of biological chemistry. 2009; 284:32015-32027
15. Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A and Koike K. MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nature communications. 2011; 2:338
16. Valdmanis PN, Gu S, Chu K, Jin L, Zhang F, Munding EM, Zhang Y, Huang Y, Kutay H, Ghoshal K, Lisowski L and Kay MA. RNA interference-induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice. Nature medicine. 2016
17. Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C and Qian C. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer letters. 2016; 371:171-181
18. Yin S, Fan Y, Zhang H, Zhao Z, Hao Y, Li J, Sun C, Yang J, Yang Z, Yang X, Lu J and Xi JJ. Differential TGFbeta pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. Nature communications. 2016; 7:11012
19. Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P and Qian C. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer letters. 2011; 310:160-169
20. Yang YM, Lee CG, Koo JH, Kim TH, Lee JM, An J, Kim KM and Kim SG. Galpha12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4alpha inactivation, which causes c-Met induction. Oncotarget. 2015; 6:19055-19069. doi: 10.18632/oncotarget.3957
21. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464:1067-1070
22. Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T, Zhang Z and Sun X. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. Journal of controlled release: official journal of the Controlled Release Society. 2014; 194:228-237
23. Tripp RA and Mark Tompkins S. Antiviral effects of inhibiting host gene expression. Current topics in microbiology and immunology. 2015; 386:459-477
24. Zhang Y, Satterlee A and Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Molecular therapy: the journal of the American Society of Gene Therapy. 2012; 20:1298-1304
25. Cooray S, Howe SJ and Thrasher AJ. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods in enzymology. 2012; 507:29-57
26. Song L, Sun S, Li B, Pan Y, Li W, Zhang K and Li J. External quality assessment for enterovirus 71 and coxsackievirus A16 detection by reverse transcription-PCR using armored RNA as a virus surrogate. Journal of clinical microbiology. 2011; 49:3591-3595
27. Li J, Sun Y, Jia T, Zhang R, Zhang K and Wang L. Messenger RNA vaccine based on recombinant MS2 viruslike particles against prostate cancer. International journal of cancer. 2014; 134:1683-1694
28. Meng S, Wei B, Xu R, Zhang K, Wang L, Zhang R and Li J. TAT peptides mediated small interfering RNA delivery to Huh-7 cells and efficiently inhibited hepatitis C virus RNA replication. Intervirology. 2009; 52:135-140
29. Wei B, Wei Y, Zhang K, Wang J, Xu R, Zhan S, Lin G, Wang W, Liu M, Wang L, Zhang R and Li J. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cellpenetrating peptide. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2009; 63:313-318
30. Pan Y, Zhang Y, Jia T, Zhang K, Li J and Wang L. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. The FEBS journal. 2012; 279:1198-1208
31. Pan Y, Jia T, Zhang Y, Zhang K, Zhang R, Li J and Wang L. MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. International journal of nanomedicine. 2012; 7:5957-5967
32. Yao Y, Jia T, Pan Y, Gou H, Li Y, Sun Y, Zhang R, Zhang K, Lin G, Xie J, Li J and Wang L. Using a novel microRNA delivery system to inhibit osteoclastogenesis. International journal of molecular sciences. 2015; 16:8337-8350
33. Chang L, Wang G, Jia T, Zhang L, Li Y, Han Y, Zhang K, Lin G, Zhang R, Li J and Wang L. Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma. Oncotarget. 2016. doi: 10.18632/oncotarget.8115
34. Tumban E, Muttil P, Escobar CA, Peabody J, Wafula D, Peabody DS and Chackerian B. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Vaccine. 2015; 33:3346-3353
35. Tumban E, Peabody J, Tyler M, Peabody DS and Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PloS one. 2012; 7:e49751
36. Tyler M, Tumban E, Peabody DS and Chackerian B. The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnology and bioengineering. 2014; 111:2398-2406
37. Nakase I, Akita H, Kogure K, Graslund A, Langel U, Harashima H and Futaki S. Efficient intracellular delivery of nucleic acid pharmaceuticals using cellpenetrating peptides. Accounts of chemical research. 2012; 45:1132-1139
38. Brooks H, Lebleu B and Vives E. Tat peptide-mediated cellular delivery: back to basics. Advanced drug delivery reviews. 2005; 57:559-577
39. Vives E, Brodin P and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. The Journal of biological chemistry. 1997; 272:16010-16017
40. Foged C, Franzyk H, Bahrami S, Frokjaer S, Jaroszewski JW, Nielsen HM and Olsen CA. Cellular uptake and membrane-destabilising properties of alpha-peptide/beta-peptoid chimeras: lessons for the design of new cellpenetrating peptides. Biochimica et biophysica acta. 2008; 1778:2487-2495
41. Ma L, Liu J, Shen J, Liu L, Wu J, Li W, Luo J, Chen Q and Qian C. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer biology & therapy. 2010; 9:554-561
42. Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo Caldeira J and Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. Journal of molecular biology. 2008; 380:252-263
43. Torchilin VP, Rammohan R, Weissig V and Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:8786-8791
44. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV and Lebleu B. Cellpenetrating peptides. A reevaluation of the mechanism of cellular uptake. The Journal of biological chemistry. 2003; 278:585-590
45. Israelow B, Mullokandov G, Agudo J, Sourisseau M, Bashir A, Maldonado AY, Dar AC, Brown BD and Evans MJ. Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. Nature communications. 2014; 5:5408
46. Li YP, Gottwein JM, Scheel TK, Jensen TB and Bukh J. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:4991-4996
47. Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, Padilla DP, Phillips B, Carter MB, Willman CL, Brinker CJ, Caldeira Jdo C, Chackerian B, Wharton W and Peabody DS. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS nano. 2011; 5:5729-5745
48. Makarova JA and Kramerov DA. Noncoding RNAs. Biochemistry Biokhimiia. 2007; 72:1161-1178
49. Kim J, Lee B, Kim JS, Yun CO, Kim JH, Lee YJ, Joo CH and Lee H. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoproteinproducing human liver cancer cells. Cancer letters. 2002; 180:23-32
50. Yuan L, Zhou C, Lu Y, Hong M, Zhang Z, Zhang Z, Chang Y, Zhang C and Li X. IFN-gamma-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1. Cancer letters. 2015; 359:136-147